A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neckTanguy Y. Seiwert, Ezra E.W. Cohen, M. Degardin et al.|Annals of Oncology|2014Cited by 182
BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.Tanguy Y. Seiwert, Ezra E.W. Cohen, Paul M. Clément et al.|Journal of Clinical Oncology|2010Cited by 39
A Randomized, Open-Label, Phase II Study of Afatinib Versus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)Tanguy Y. Seiwert, Ezra E.W. Cohen, E. Ehrnrooth et al.|Annals of Oncology|2012Cited by 17